dc.contributor.author | Scherpereel, A | |
dc.contributor.author | Antonia, S | |
dc.contributor.author | Bautista, Y | |
dc.contributor.author | Grossi, F | |
dc.contributor.author | Kowalski, D | |
dc.contributor.author | Zalcman, G | |
dc.contributor.author | Nowak, AK | |
dc.contributor.author | Fujimoto, N | |
dc.contributor.author | Peters, S | |
dc.contributor.author | Tsao, AS | |
dc.contributor.author | Mansfield, AS | |
dc.contributor.author | Popat, S | |
dc.contributor.author | Sun, X | |
dc.contributor.author | Lawrance, R | |
dc.contributor.author | Zhang, X | |
dc.contributor.author | Daumont, MJ | |
dc.contributor.author | Bennett, B | |
dc.contributor.author | McKenna, M | |
dc.contributor.author | Baas, P | |
dc.coverage.spatial | Ireland | |
dc.date.accessioned | 2022-07-13T14:27:51Z | |
dc.date.available | 2022-07-13T14:27:51Z | |
dc.date.issued | 2022-05-01 | |
dc.identifier | S0169-5002(22)00381-6 | |
dc.identifier.citation | Lung Cancer, 2022, 167 pp. 8 - 16 | en_US |
dc.identifier.issn | 0169-5002 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5228 | |
dc.identifier.eissn | 1872-8332 | |
dc.identifier.eissn | 1872-8332 | |
dc.identifier.doi | 10.1016/j.lungcan.2022.03.012 | |
dc.description.abstract | OBJECTIVE: In CheckMate 743 (NCT02899299), nivolumab + ipilimumab significantly prolonged overall survival in patients with unresectable malignant pleural mesothelioma (MPM). We present patient-reported outcomes (PROs). MATERIALS AND METHODS: Patients (N = 605) were randomized to nivolumab + ipilimumab or chemotherapy. Changes in disease-related symptom burden and health-related quality of life (HRQoL) were evaluated descriptively using the Lung Cancer Symptom Scale (LCSS)-Mesothelioma (Meso) average symptom burden index (ASBI), LCSS-Meso 3-item global index (3-IGI), 3-level EuroQol 5-dimensional (EQ-5D-3L) visual analog score (VAS), and EQ-5D-3L utility index. PROs were assessed at baseline and every 2 (nivolumab + ipilimumab) or 3 weeks (chemotherapy) through 12 weeks, every 6 weeks through 12 months, every 12 weeks thereafter, and at specified follow-ups. Mixed-effect model repeated measures (MMRM) and time to deterioration analyses were conducted. RESULTS: Completion rates were generally >80%. LCSS-Meso ASBI mean changes from baseline trended to improve over time with nivolumab + ipilimumab and deteriorate with chemotherapy, but did not meet clinically important difference thresholds [±10 score change]. EQ-5D-3L VAS mean scores improved over time with nivolumab + ipilimumab; by week 60, patients had scores consistent with United Kingdom normal population values. MMRM analyses favored nivolumab + ipilimumab for all individual symptoms except cough. Nivolumab + ipilimumab delayed time to definitive deterioration in HRQoL (hazard ratio 0.52 [95% confidence interval 0.36-0.74]) and showed a trend in symptom delay versus chemotherapy. CONCLUSIONS: Nivolumab + ipilimumab decreased the risk of deterioration in disease-related symptoms and HRQoL versus chemotherapy and maintained QoL in patients with unresectable MPM. | |
dc.format | Print-Electronic | |
dc.format.extent | 8 - 16 | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | ELSEVIER IRELAND LTD | en_US |
dc.relation.ispartof | Lung Cancer | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) | |
dc.subject | EQ-5D | |
dc.subject | Immune checkpoint inhibitors | |
dc.subject | Immuno-oncology | |
dc.subject | Immunotherapy | |
dc.subject | Lung Cancer Symptom Scale | |
dc.subject | Overall survival | |
dc.subject | Programmed cell death (PD)-1 inhibitor | |
dc.subject | Quality of life | |
dc.subject | Symptom burden | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Humans | |
dc.subject | Ipilimumab | |
dc.subject | Lung Neoplasms | |
dc.subject | Mesothelioma | |
dc.subject | Mesothelioma, Malignant | |
dc.subject | Nivolumab | |
dc.subject | Patient Reported Outcome Measures | |
dc.subject | Quality of Life | |
dc.title | First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-03-12 | |
dc.date.updated | 2022-07-13T14:24:14Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1016/j.lungcan.2022.03.012 | en_US |
rioxxterms.licenseref.startdate | 2022-05-01 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/35367910 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.) | |
pubs.publication-status | Published | |
pubs.volume | 167 | |
dc.contributor.icrauthor | Popat, Sanjay | |
icr.provenance | Deposited by Mr Arek Surman on 2022-07-13. Deposit type is initial. No. of files: 1. Files: 1-s2.0-S0169500222003816-main.pdf | |